使用铜和纳米颗粒的循环-His-Phe复合物具有抗菌性质,并针对骨肉瘤细胞具有向抗癌潜力
Chrysanthi Pinelopi Apostolidou1,2, Georgios Charalambidis3,4, Aikaterini Gialouri1,5
1Department of Materials Science and Engineering, University of Crete, Voutes Campus, 70013 Heraklion, Greece.
Biomolecules
|February 27, 2026
概括
循环二载体提供铜和纳米颗粒以向骨髓瘤细胞. 这种pH响应系统表现出对癌症和纤维细胞毒性较低的微生物的双重作用.
科学领域:
- 生物材料科学 生物材料科学
- 纳米医学是一种纳米医学.
- 癌症治疗 癌症治疗
背景情况:
- 骨髓瘤是一种具有攻击性的骨癌,治疗选择有限.
- 系统性毒性是常规癌症疗法的一个主要问题.
- 有针对性的金属纳米颗粒的输送可以克服这些局限性.
研究的目的:
- 开发一种pH响应的生物分子载体,用于和铜纳米颗粒的定向输送.
- 为了评估这些纳米颗粒对骨髓瘤细胞和微生物的疗效.
- 评估载体的生物相容性和安全性.
主要方法:
- 一种含有histidine的循环二 (cyclo-(histidine-phenylalanine,cHF) 用于结合铜和纳米颗粒 (CuNPs, ZnNPs).
- 进行了cHF-金属纳米粒子复合体 (cHF-CuNPs,cHF-ZnNPs) 的表征.
- 在体外研究中评估了对大肠杆菌和金黄色葡萄球菌的抗菌活性.
- 细胞毒性测定是在不同的pH值下对L929纤维细胞和MG-63骨肉瘤细胞进行的.
主要成果:
- cHF自组装成粉样类纤维,形成稳定的cHF-CuNP和cHF-ZnNP.
- 复合纳米颗粒对测试的细菌表现出细菌静止活性.
- 最佳度对纤维细胞具有较低的细胞毒性,但对骨髓瘤细胞具有很高的疗效.
- 细胞毒性在pH值6.4显著增强,模仿瘤微环境.
结论:
- 该cHF作为一个细胞相容,pH响应金属纳米颗粒的载体.
- 开发的cHF金属纳米颗粒具有针对微生物感染和骨肉瘤的双重功能.
- 这种方法为局部癌症治疗提供了一个有希望的策略,系统毒性降低.
更多相关视频
08:22Studying Copper Nanoparticle-Induced Programmed Cell Death in Bacteria
Published on: May 16, 2025
612
11:04Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
Published on: September 7, 2019
9.9K
相关概念视频
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K